FDA delays panel review of Cymbalta for chronic pain

01/5/2010 | Reuters

The FDA called off a panel review regarding the use of Eli Lilly and Co.'s antidepressant Cymbalta for chronic pain to give the agency more time to evaluate safety information on the indication. The company said it already submitted additional studies and continues "routine safety monitoring that isn't specific to the chronic pain application."

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA